Two medications manufactured by AbbVie, Vraylar and Linzess, are among 15 new drugs selected for the federal government’s new price negotiation program. Vraylar, which North Chicago-based AbbVie ...

It also includes data from a long-term, open-label study that focused on the safety and tolerability of the drug over 26 weeks. Vraylar is now one of AbbVie's fastest-growing products with sales ...

The treatment effect was mixed however, as has been seen in other trials of the drug in this setting. There was a significant effect at the lower 1.5mg/day dose of Vraylar, with 44% of patients ...

Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and 14 other medications, a cost-saving move that would take effect in 2027.

Latuda. Talk with your doctor about which medication is best for your condition. Abilify contains the active ingredient aripiprazole. But Vraylar contains the active ingredient cariprazine.

Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion. The biggest driver was the rights Caplyta which has ...

Vraylar; Janumet and Janumet XR; and Otezla.Ozempic and Wegovy are made by Novo Nordisk, which is based in Denmark and has U.S. headquarters Plainsboro, New Jersey. Popular weight loss drugs like ...